Symbols / NTRA
NTRA Chart
About
Natera, Inc., a diagnostics company, provides molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born. The company also provides Signatera molecular residual disease test for assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based genomic profiling test, that provides insight into genomic alterations and biomarkers; Prospera to assess active rejection in patients who have undergone kidney, heart, and lung transplantation; and Renasight, a kidney gene panel test. In addition, it offers Constellation, a cloud-based software product. It serves independent laboratories, national and regional reference laboratories, medical centers and physician practices, research laboratories, and pharmaceutical companies through its direct sales force, and a network of laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was formerly known as Gene Security Network, LLC and changed its name to Natera, Inc. in January 2012. Natera, Inc. was founded in 2003 and is headquartered in Austin, Texas.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Diagnostics & Research | Market Cap | 29.22B |
| Enterprise Value | 28.07B | Income | -309.19M | Sales | 2.12B |
| Book/sh | 9.11 | Cash/sh | 7.55 | Dividend Yield | — |
| Payout | 0.00% | Employees | 4424 | IPO | — |
| P/E | — | Forward P/E | -105.48 | PEG | — |
| P/S | 13.80 | P/B | 23.01 | P/C | — |
| EV/EBITDA | -88.23 | EV/Sales | 13.26 | Quick Ratio | 3.01 |
| Current Ratio | 3.27 | Debt/Eq | 15.87 | LT Debt/Eq | — |
| EPS (ttm) | -2.28 | EPS next Y | -1.99 | EPS Growth | — |
| Revenue Growth | 34.70% | Earnings | 2026-02-26 | ROA | -12.89% |
| ROE | -29.02% | ROIC | — | Gross Margin | 63.66% |
| Oper. Margin | -16.48% | Profit Margin | -14.61% | Shs Outstand | 139.45M |
| Shs Float | 133.76M | Short Float | 2.55% | Short Ratio | 3.15 |
| Short Interest | — | 52W High | 256.36 | 52W Low | 125.38 |
| Beta | 1.63 | Avg Volume | 1.17M | Volume | 666.39K |
| Target Price | $257.20 | Recom | Strong_buy | Prev Close | $209.35 |
| Price | $209.53 | Change | 0.09% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$257.20
Mean price target
2. Current target
$209.53
Latest analyst target
3. DCF / Fair value
$23.32
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$209.53
Low
$186.00
High
$300.00
Mean
$257.20
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-01-07 | init | Citigroup | — → Buy | $300 |
| 2026-01-05 | main | Guggenheim | Buy → Buy | $270 |
| 2025-12-22 | main | Canaccord Genuity | Buy → Buy | $285 |
| 2025-12-15 | main | Barclays | Overweight → Overweight | $270 |
| 2025-12-15 | main | JP Morgan | Overweight → Overweight | $260 |
| 2025-12-15 | main | Wells Fargo | Equal-Weight → Equal-Weight | $205 |
| 2025-12-08 | main | Canaccord Genuity | Buy → Buy | $250 |
| 2025-12-05 | main | BTIG | Buy → Buy | $260 |
| 2025-12-02 | main | Morgan Stanley | Overweight → Overweight | $265 |
| 2025-11-25 | main | JP Morgan | Overweight → Overweight | $250 |
| 2025-11-18 | main | UBS | Buy → Buy | $280 |
| 2025-11-13 | main | Stephens & Co. | Overweight → Overweight | $235 |
| 2025-11-11 | main | Piper Sandler | Overweight → Overweight | $230 |
| 2025-11-11 | main | Morgan Stanley | Overweight → Overweight | $220 |
| 2025-11-07 | main | Canaccord Genuity | Buy → Buy | $250 |
| 2025-11-07 | main | JP Morgan | Overweight → Overweight | $240 |
| 2025-11-07 | main | Wells Fargo | Equal-Weight → Equal-Weight | $190 |
| 2025-11-07 | main | Barclays | Overweight → Overweight | $230 |
| 2025-11-07 | main | Evercore ISI Group | Outperform → Outperform | $250 |
| 2025-11-07 | main | BTIG | Buy → Buy | $230 |
- Natera Earnings: What To Look For From NTRA - TradingView Wed, 25 Feb 2026 03
- Is Natera (NTRA) Fairly Priced After Recent Share Price Pullback? - Yahoo Finance ue, 24 Feb 2026 02
- Chemo cut by two-thirds with ctDNA-guided care in head and neck cancer study - Stock Titan ue, 24 Feb 2026 11
- NTRA Stock Falls -15% In 9-day Spree On 'Sell' Rating And Insider Sales - Trefis Wed, 04 Feb 2026 08
- Natera, Inc. (NTRA) Stock Analysis: High Growth Potential With 21.25% Upside - DirectorsTalk Interviews Mon, 23 Feb 2026 19
- Billionaire Stanley Druckenmiller Is Betting Big on These 2 Stocks - The Motley Fool Sun, 22 Feb 2026 00
- Unveiling Natera (NTRA) Q4 Outlook: Wall Street Estimates for Key Metrics - Nasdaq Mon, 23 Feb 2026 14
- How Surging Signatera Oncology Volumes At Natera (NTRA) Have Changed Its Investment Story - simplywall.st ue, 24 Feb 2026 00
- Natera CEO sells $1.4m in NTRA stock - Investing.com hu, 29 Jan 2026 08
- Insider Sale: PRESIDENT of $NTRA Sells 2,415 Shares | NTRA Stock News - Quiver Quantitative hu, 05 Feb 2026 08
- NTRA Stock Falls -19% In 10-day Spree On Insider Selling And ‘Sell’ Rating - Trefis Fri, 06 Feb 2026 08
- Natera, Inc. (NTRA) Stock Analysis: Unpacking the 24.72% Potential Upside in the Diagnostics Powerhouse - DirectorsTalk Interviews Mon, 16 Feb 2026 08
- Natera, Inc. Stock (NTRA) Opinions on Foresight Acquisition and Signatera Data - Quiver Quantitative Mon, 08 Dec 2025 08
- Bladder cancer test Signatera heads to FDA after phase 3 survival gains - Stock Titan Mon, 02 Feb 2026 08
- Why Natera (NTRA) Stock Is Down Today - Yahoo Finance Fri, 29 Aug 2025 07
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 90024 | 20770419.0 | — | Sale at price 229.08 - 234.00 per share. | CHAPMAN STEVEN LEONARD | Chief Executive Officer | — | 2026-02-03 00:00:00 | D |
| 1 | 1334 | 307845.0 | — | Sale at price 230.77 per share. | RABINOWITZ DANIEL A | Officer | — | 2026-02-03 00:00:00 | D |
| 2 | 3594 | 830279.0 | — | Sale at price 230.77 - 231.14 per share. | FESKO JOHN | President | — | 2026-02-03 00:00:00 | D |
| 3 | 4639 | 1072538.0 | — | Sale at price 228.50 - 234.00 per share. | MOSHKEVICH SOLOMON | Officer | — | 2026-02-03 00:00:00 | D |
| 4 | 6939 | 1580926.0 | — | Sale at price 225.25 - 230.77 per share. | BROPHY MICHAEL BURKES | Chief Financial Officer | — | 2026-02-03 00:00:00 | D |
| 5 | 435 | 100384.0 | — | Sale at price 230.77 per share. | SHEENA JONATHAN | Director | — | 2026-02-03 00:00:00 | D |
| 6 | 70 | — | — | Stock Award(Grant) at price 0.00 per share. | BERTAGNOLLI MONICA | Director | — | 2026-01-30 00:00:00 | D |
| 7 | 97 | — | — | Stock Award(Grant) at price 0.00 per share. | CHAPMAN ROWAN E | Director | — | 2026-01-30 00:00:00 | D |
| 8 | 70 | — | — | Stock Award(Grant) at price 0.00 per share. | BAYNES ROY D | Director | — | 2026-01-30 00:00:00 | D |
| 9 | 6135 | — | — | Stock Award(Grant) at price 0.00 per share. | FESKO JOHN | President | — | 2026-01-30 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.21 | 0.21 | 0.00 | 0.27 |
| NormalizedEBITDA | -148.08M | -397.80M | -520.80M | -451.54M |
| TotalUnusualItems | 0.00 | 0.00 | ||
| TotalUnusualItemsExcludingGoodwill | 0.00 | 0.00 | ||
| NetIncomeFromContinuingOperationNetMinorityInterest | -190.43M | -434.80M | -547.80M | -471.72M |
| ReconciledDepreciation | 30.97M | 24.10M | 16.70M | 11.25M |
| ReconciledCostOfRevenue | 673.75M | 589.83M | 456.26M | 318.42M |
| EBITDA | -148.08M | -397.80M | -520.80M | -451.54M |
| EBIT | -179.05M | -421.89M | -537.50M | -462.79M |
| NetInterestIncome | 32.56M | 11.71M | -5.78M | -2.92M |
| InterestExpense | 10.69M | 12.64M | 9.32M | 8.30M |
| InterestIncome | 43.25M | 24.35M | 3.54M | 5.38M |
| NormalizedIncome | -190.43M | -434.80M | -547.80M | -471.72M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -190.43M | -434.80M | -547.80M | -471.72M |
| TotalExpenses | 1.92B | 1.53B | 1.36B | 1.09B |
| TotalOperatingIncomeAsReported | -222.29M | -446.25M | -541.04M | -468.17M |
| DilutedAverageShares | 124.72M | 115.00M | 98.41M | 90.56M |
| BasicAverageShares | 124.72M | 115.00M | 98.41M | 90.56M |
| DilutedEPS | -1.53 | -3.78 | -5.57 | -5.21 |
| BasicEPS | -1.53 | -3.78 | -5.57 | -5.21 |
| DilutedNIAvailtoComStockholders | -190.43M | -434.80M | -547.80M | -471.72M |
| NetIncomeCommonStockholders | -190.43M | -434.80M | -547.80M | -471.72M |
| NetIncome | -190.43M | -434.80M | -547.80M | -471.72M |
| NetIncomeIncludingNoncontrollingInterests | -190.43M | -434.80M | -547.80M | -471.72M |
| NetIncomeContinuousOperations | -190.43M | -434.80M | -547.80M | -471.72M |
| TaxProvision | 695.00K | 271.00K | 978.00K | 618.00K |
| PretaxIncome | -189.73M | -434.53M | -546.82M | -471.10M |
| OtherIncomeExpense | 5.38M | |||
| OtherNonOperatingIncomeExpenses | 5.38M | |||
| SpecialIncomeCharges | 0.00 | 0.00 | ||
| GainOnSaleOfBusiness | 0.00 | |||
| NetNonOperatingInterestIncomeExpense | 32.56M | 11.71M | -5.78M | -2.92M |
| InterestExpenseNonOperating | 10.69M | 12.64M | 9.32M | 8.30M |
| InterestIncomeNonOperating | 43.25M | 24.35M | 3.54M | 5.38M |
| OperatingIncome | -222.29M | -446.25M | -541.04M | -468.17M |
| OperatingExpense | 1.25B | 938.99M | 905.01M | 775.24M |
| ResearchAndDevelopment | 404.14M | 320.68M | 316.42M | 264.21M |
| SellingGeneralAndAdministration | 841.31M | 618.31M | 588.59M | 511.03M |
| GrossProfit | 1.02B | 492.74M | 363.97M | 307.07M |
| CostOfRevenue | 673.75M | 589.83M | 456.26M | 318.42M |
| TotalRevenue | 1.70B | 1.08B | 820.22M | 625.49M |
| OperatingRevenue | 1.70B | 1.08B | 820.22M | 625.49M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 132.65M | 119.58M | 111.25M | 95.14M |
| ShareIssued | 132.65M | 119.58M | 111.25M | 95.14M |
| NetDebt | 246.06M | |||
| TotalDebt | 187.12M | 441.99M | 446.22M | 397.23M |
| TangibleBookValue | 1.20B | 765.33M | 705.74M | 653.30M |
| InvestedCapital | 1.28B | 1.13B | 1.07B | 983.75M |
| WorkingCapital | 1.03B | 951.27M | 901.32M | 874.18M |
| NetTangibleAssets | 1.20B | 765.33M | 705.74M | 653.30M |
| CapitalLeaseObligations | 106.76M | 78.65M | 84.22M | 66.79M |
| CommonStockEquity | 1.20B | 765.33M | 705.74M | 653.30M |
| TotalCapitalization | 1.20B | 1.05B | 987.40M | 933.70M |
| TotalEquityGrossMinorityInterest | 1.20B | 765.33M | 705.74M | 653.30M |
| StockholdersEquity | 1.20B | 765.33M | 705.74M | 653.30M |
| GainsLossesNotAffectingRetainedEarnings | -344.00K | -3.08M | -16.36M | -2.29M |
| OtherEquityAdjustments | -344.00K | -3.08M | -16.36M | -2.29M |
| RetainedEarnings | -2.57B | -2.38B | -1.94B | -1.39B |
| AdditionalPaidInCapital | 3.76B | 3.15B | 2.66B | 2.05B |
| CapitalStock | 12.00K | 11.00K | 11.00K | 10.00K |
| CommonStock | 12.00K | 11.00K | 11.00K | 10.00K |
| TotalLiabilitiesNetMinorityInterest | 465.31M | 676.37M | 688.73M | 583.18M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 121.27M | 369.10M | 378.23M | 364.23M |
| OtherNonCurrentLiabilities | 1.48M | |||
| NonCurrentDeferredLiabilities | 24.68M | 19.13M | 20.00M | 21.32M |
| NonCurrentDeferredRevenue | 24.68M | 19.13M | 20.00M | 21.32M |
| LongTermDebtAndCapitalLeaseObligation | 96.59M | 349.97M | 358.23M | 341.43M |
| LongTermCapitalLeaseObligation | 96.59M | 67.03M | 76.58M | 61.04M |
| LongTermDebt | 282.94M | 281.65M | 280.39M | |
| CurrentLiabilities | 344.05M | 307.27M | 310.50M | 218.96M |
| CurrentDeferredLiabilities | 19.75M | 16.61M | 10.78M | 7.40M |
| CurrentDeferredRevenue | 19.75M | 16.61M | 10.78M | 7.40M |
| CurrentDebtAndCapitalLeaseObligation | 90.53M | 92.02M | 87.99M | 55.80M |
| CurrentCapitalLeaseObligation | 10.17M | 11.62M | 7.64M | 5.75M |
| CurrentDebt | 80.36M | 80.40M | 80.35M | 50.05M |
| OtherCurrentBorrowings | 80.35M | 50.05M | ||
| LineOfCredit | 80.36M | 80.40M | 80.35M | 50.05M |
| PensionandOtherPostRetirementBenefitPlansCurrent | 62.11M | 45.86M | 44.01M | 40.94M |
| CurrentProvisions | 11.28M | 23.25M | 18.95M | 17.21M |
| PayablesAndAccruedExpenses | 160.37M | 129.54M | 148.78M | 97.60M |
| CurrentAccruedExpenses | 121.03M | 110.81M | 113.31M | 68.16M |
| InterestPayable | 0.00 | 1.08M | 1.08M | 1.08M |
| Payables | 39.34M | 18.73M | 35.47M | 29.44M |
| TotalTaxPayable | 4.42M | 3.73M | 4.32M | 2.23M |
| IncomeTaxPayable | 4.32M | 2.23M | ||
| AccountsPayable | 34.92M | 15.00M | 31.15M | 27.21M |
| TotalAssets | 1.66B | 1.44B | 1.39B | 1.24B |
| TotalNonCurrentAssets | 284.92M | 183.15M | 182.66M | 143.35M |
| OtherNonCurrentAssets | 36.72M | 15.40M | 18.33M | 18.82M |
| NetPPE | 248.19M | 167.75M | 164.33M | 124.53M |
| AccumulatedDepreciation | -78.42M | -56.29M | -35.70M | -19.41M |
| GrossPPE | 326.61M | 224.04M | 200.03M | 143.94M |
| Leases | 48.57M | 39.00M | 29.75M | 13.64M |
| ConstructionInProgress | 58.46M | 29.39M | 25.37M | 30.28M |
| OtherProperties | 86.15M | 56.54M | 71.87M | 59.01M |
| MachineryFurnitureEquipment | 133.43M | 99.11M | 73.03M | 41.01M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 1.38B | 1.26B | 1.21B | 1.09B |
| OtherCurrentAssets | 48.63M | 60.52M | 33.63M | 29.64M |
| RestrictedCash | 86.00K | 228.00K | ||
| PrepaidAssets | 29.64M | |||
| Inventory | 44.74M | 40.76M | 35.41M | 26.91M |
| Receivables | 314.17M | 278.29M | 244.38M | 122.07M |
| AccountsReceivable | 314.17M | 278.29M | 244.38M | 122.07M |
| AllowanceForDoubtfulAccountsReceivable | -7.26M | -6.48M | -3.83M | -2.43M |
| GrossAccountsReceivable | 321.42M | 284.77M | 248.22M | 124.50M |
| CashCashEquivalentsAndShortTermInvestments | 968.28M | 878.98M | 898.39M | 914.28M |
| OtherShortTermInvestments | 22.69M | 236.88M | 432.30M | 829.90M |
| CashAndCashEquivalents | 945.59M | 642.10M | 466.09M | 84.39M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | 58.75M | -286.15M | -479.20M | -376.27M |
| RepaymentOfDebt | -82.00K | 0.00 | 0.00 | 0.00 |
| IssuanceOfDebt | 0.00 | 0.00 | 30.00M | 0.00 |
| IssuanceOfCapitalStock | 0.00 | 235.44M | 433.19M | 550.82M |
| CapitalExpenditure | -76.92M | -39.20M | -47.70M | -41.03M |
| InterestPaidSupplementalData | 7.90M | 11.35M | 8.06M | 7.08M |
| IncomeTaxPaidSupplementalData | 1.31M | 295.00K | 549.00K | 283.00K |
| EndCashPosition | 945.59M | 642.10M | 466.09M | 84.61M |
| BeginningCashPosition | 642.10M | 466.09M | 84.61M | 48.85M |
| ChangesInCash | 303.49M | 176.00M | 381.48M | 35.76M |
| FinancingCashFlow | 30.20M | 254.46M | 482.64M | 576.19M |
| CashFlowFromContinuingFinancingActivities | 30.20M | 254.46M | 482.64M | 576.19M |
| ProceedsFromStockOptionExercised | 30.29M | 19.02M | 19.45M | 25.37M |
| NetCommonStockIssuance | 0.00 | 235.44M | 433.19M | 550.82M |
| CommonStockIssuance | 0.00 | 235.44M | 433.19M | 550.82M |
| NetIssuancePaymentsOfDebt | -82.00K | 0.00 | 30.00M | 0.00 |
| NetShortTermDebtIssuance | 0.00 | 30.00M | 0.00 | |
| ShortTermDebtIssuance | 0.00 | 30.00M | 0.00 | |
| NetLongTermDebtIssuance | -82.00K | 0.00 | 30.00M | 0.00 |
| LongTermDebtPayments | -82.00K | 0.00 | 0.00 | 0.00 |
| LongTermDebtIssuance | 0.00 | 0.00 | 30.00M | 0.00 |
| InvestingCashFlow | 137.62M | 168.50M | 330.34M | -205.19M |
| CashFlowFromContinuingInvestingActivities | 137.62M | 168.50M | 330.34M | -205.19M |
| NetOtherInvestingChanges | -8.56M | |||
| NetInvestmentPurchaseAndSale | 214.54M | 207.70M | 378.04M | -155.60M |
| SaleOfInvestment | 339.22M | 306.00M | 464.98M | 720.49M |
| PurchaseOfInvestment | -124.68M | -98.30M | -86.95M | -876.10M |
| NetBusinessPurchaseAndSale | 0.00 | |||
| SaleOfBusiness | 0.00 | |||
| NetIntangiblesPurchaseAndSale | -10.49M | 0.00 | 0.00 | |
| PurchaseOfIntangibles | -10.49M | 0.00 | 0.00 | |
| NetPPEPurchaseAndSale | -66.42M | -39.20M | -47.70M | -41.03M |
| PurchaseOfPPE | -66.42M | -39.20M | -47.70M | -41.03M |
| OperatingCashFlow | 135.66M | -246.96M | -431.50M | -335.24M |
| CashFlowFromContinuingOperatingActivities | 135.66M | -246.96M | -431.50M | -335.24M |
| ChangeInWorkingCapital | 2.14M | -47.95M | -83.15M | -45.60M |
| ChangeInOtherWorkingCapital | 852.00K | 4.96M | 2.06M | -44.21M |
| ChangeInOtherCurrentLiabilities | -16.82M | -12.45M | -10.00M | -10.30M |
| ChangeInOtherCurrentAssets | 0.00 | 8.35M | 622.00K | 0.00 |
| ChangeInPayablesAndAccruedExpense | 47.16M | 16.51M | 56.18M | 62.47M |
| ChangeInAccruedExpense | 33.95M | 31.97M | 50.72M | 43.25M |
| ChangeInPayable | 13.21M | -15.46M | 5.46M | 19.22M |
| ChangeInAccountPayable | 13.21M | -15.46M | 5.46M | 19.22M |
| ChangeInPrepaidAssets | 10.81M | -26.07M | -1.20M | -3.18M |
| ChangeInInventory | -3.98M | -5.35M | -8.50M | -6.88M |
| ChangeInReceivables | -35.88M | -33.90M | -122.31M | -43.51M |
| ChangesInAccountReceivables | -35.88M | -33.90M | -122.31M | -43.51M |
| OtherNonCashItems | 18.71M | 18.54M | 24.62M | 47.85M |
| StockBasedCompensation | 274.43M | 191.81M | 152.38M | 115.22M |
| UnrealizedGainLossOnInvestmentSecurities | -2.00K | -11.00K | ||
| ProvisionandWriteOffofAssets | 1.77M | -156.00K | ||
| AssetImpairmentCharge | 0.00 | |||
| AmortizationOfSecurities | -618.00K | 1.09M | 4.84M | 7.81M |
| DepreciationAmortizationDepletion | 30.97M | 24.10M | 16.70M | 11.25M |
| DepreciationAndAmortization | 30.97M | 24.10M | 16.70M | 11.25M |
| OperatingGainsLosses | 462.00K | 265.00K | 904.00K | -57.00K |
| GainLossOnInvestmentSecurities | 906.00K | -46.00K | ||
| NetForeignCurrencyExchangeGainLoss | 462.00K | 265.00K | -2.00K | -11.00K |
| GainLossOnSaleOfBusiness | 0.00 | |||
| NetIncomeFromContinuingOperations | -190.43M | -434.80M | -547.80M | -471.72M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for NTRA
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|